Oridivus
Oridivus is pioneering the development of the first FDA-approved oral wound healing therapy, with a mission to transform pediatric oral health outcomes. The company addresses critical unmet needs in oral surgery by accelerating healing, reducing pain, and minimizing opioid dependency, especially in young patients. Oridivus leverages advanced biomaterials and immunomodulatory compounds to provide faster, safer, and more effective recovery for procedures such as wisdom tooth extractions, cleft palate repairs, and oral trauma. Their vision is to improve quality of life for children and young adults, break the cycle of opioid dependency, and set new standards in oral wound care.
Oridivus
Oridivus is currently seeking investment
Oridivus is seeking a seed investment in the range of 1m-5m
Patents
Uniaxially-aligned nanofiber scaffolds and methods for producing and using same
2025-04-01 • US-12263277-B2
View DetailsWhat We Do
ORD002 is a revolutionary oral wound healing system that combines FTY720 (fingolimod), an FDA-approved immunomodulatory agent, with an advanced electrospun nanofiber scaffold. This product accelerates oral mucosal healing by 30%, reduces inflammation and pain, and significantly decreases the need for opioid prescriptions after oral surgery. It is designed for use in procedures such as wisdom tooth extractions, cleft palate repairs, and oral trauma, offering faster healing, reduced complications, and improved patient outcomes.
Battlefield Resuscitation
Psychological and Cognitive Health and Performance
Key People
News & Updates
Oridivus is bringing to market the first FDA-approved therapy specifically for oral wound healing, addressing a critical gap in pediatric and young adult care.
ORD002 has completed Phase I safety studies and is currently enrolling in Phase II efficacy studies, with plans for large-scale Phase III trials. The technology has demonstrated accelerated healing, reduced pain, and a dramatic reduction in opioid prescription rates in preliminary studies.
A white paper examining the unique characteristics of oral mucosa wound healing in children undergoing cleft palate surgery, identifying key factors that influence healing outcomes, and presenting evidence-based strategies for optimizing recovery. Highlights the challenges of pediatric oral wound healing and the potential of advanced technologies like FTY720-loaded nanofiber sutures.
This white paper presents ORD002, a bioactive wound healing system utilizing FTY720-loaded electrospun nanofibers, which accelerates healing, reduces pain, and virtually eliminates the need for opioid prescriptions after wisdom tooth extraction. It details the technology's mechanism, clinical benefits, and its potential to address the opioid epidemic.
A presentation outlining Oridivus' mission, the unmet needs in pediatric oral wound healing, and the impact of their FDA-approved therapy on reducing pain, complications, and opioid dependency in children and young adults.